

References

1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. *CA Cancer J Clin*, 2018. 68(1): p. 7-30.
2. Keegan, T.H., et al., Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. *Cancer*, 2016. 122(7): p. 1009-16.
3. Alvarez, E., et al., Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers. *Cancer*, 2017. 123(13): p. 2516-2523.
4. Hudson, M.M., et al., Clinical ascertainment of health outcomes among adults treated for childhood cancer. *JAMA*, 2013. 309(22): p. 2371-2381.
5. Chemaitilly, W., et al., Endocrine late effects in childhood cancer survivors. *J Clin Oncol*, 2018: p. JCO2017763268.
6. Faubion, S.S., C.L. Loprinzi, and K.J. Ruddy, Management of hormone deprivation symptoms after cancer. *Mayo Clin Proc*, 2016. 91(8): p. 1133-46.
7. Practice Committees of American Society for Reproductive, M. and T. Society for Assisted Reproductive, Mature oocyte cryopreservation: a guideline. *Fertil Steril*, 2013. 99(1): p. 37-43.

References

8. Oktay, K., et al., Fertility preservation in patients with cancer: ASCO clinical practice guideline update. *J Clin Oncol*, 2018. 36(19): p. 1994-2001.
9. Djaladat, H., Organ-sparing surgery for testicular tumours. *Curr Opin Urol*, 2015. 25(2): p. 116-20.
10. Ntali, G. and N. Karavitaki, Efficacy and complications of pituitary irradiation. *Endocrinol Metab Clin North Am*, 2015. 44(1): p. 117-26.
11. Meistrich, M.L., Effects of chemotherapy and radiotherapy on spermatogenesis in humans, in *Fertil Steril*. 2013. p. 1180-6.
12. Howell, S.J. and S.M. Shalet, Spermatogenesis after cancer treatment: damage and recovery. *J Natl Cancer Inst Monogr*, 2005(34): p. 12-7.
13. Green, D.M., et al., Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. *Lancet Oncol*, 2014. 15(11): p. 1215-23.
14. Aldrink, J.H., et al., Using quality improvement methodology to improve ovarian salvage for benign ovarian masses. *J Pediatr Surg*, 2017.
15. Luczak, J. and M. Baglaj, Selecting treatment method for ovarian masses in children - 24 years of experience. *J Ovarian Res*, 2017. 10(1): p. 59.

References

16. Gershenson, D.M., Management of borderline ovarian tumours. *Best Pract Res Clin Obstet Gynaecol*, 2017. 41: p. 49-59.
17. Rosendahl, M., M.K. Simonsen, and J.J. Kjer, The influence of unilateral oophorectomy on the age of menopause. *Climacteric*, 2017: p. 1-5.
18. Bjelland, E.K., et al., Is unilateral oophorectomy associated with age at menopause? A population study (the HUNT2 Survey). *Hum Reprod*, 2014. p. 835-841.
19. diZerega, G.S., The peritoneum and its response to surgical injury. *Prog Clin Biol Res*, 1990. 358: p. 1-11.
20. Practice Committee of the American Society for Reproductive Medicine. Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery. *Fertil Steril*, 2007. 88(1): p. 21-6.
21. Meirow, D. and D. Nugent, The effects of radiotherapy and chemotherapy on female reproduction. *Hum Reprod Update*, 2001. 7(6): p. 535-543.
22. Meirow, D., et al., Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. *Hum Reprod*, 2007. 22(6): p. 1626-33.
23. Wallace, W.H., et al., Gonadal dysfunction due to cis-platinum. *Med Pediatr Oncol*, 1989. 17(5): p. 409-13.

References

24. van Dorp, W., et al., Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: A report from the International Late effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. *J Clin Oncol*, 2016. 34(28): p. 3440-+.
25. Wallace, W.H., et al., Predicting age of ovarian failure after radiation to a field that includes the ovaries. *Int J Radiat Oncol Biol Phys*, 2005. 62(3): p. 738-44.
26. Larsen, E.C., et al., Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. *Acta Obstetricia Et Gynecologica Scandinavica*, 2004. 83(1): p. 96-102.
27. Green, D.M., et al., Fertility of female survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. *J Clin Oncol*, 2009. 27(16): p. 2677-2685.
28. Green, D.M., et al., Quantifying alkylating agent exposure: Evaluation of the cyclophosphamide equivalent dose: A report from the Childhood Cancer Survivor Study. *J Clin Oncol*, 2011. 29(15).
29. Green, D.M., et al., The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report From the Childhood Cancer Survivor Study. *Pediatr Blood Cancer*, 2014. 61(1): p. 53-67.

References

30. Meiorow, D., et al., Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. *Cancer*, 2006. 107(7): p. 1634-41.
31. Eifel, P., et al., National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. *J Natl Cancer Inst*, 2001. 93(13): p. 979-89.
32. Goldhirsch, A., et al., Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. *J Clin Oncol*, 2001. 19(18): p. 3817-27.
33. Turner, N.H., et al., Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. *Ann Oncol*, 2013. 24(9): p. 2224-35.
34. Del Mastro, L., et al., Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. *Cancer Treat Rev*, 2014. 40(5): p. 675-83.

References

35. Oktay, K., et al., Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. *Oncologist*, 2007. 12(9): p. 1055-66.
36. Moore, H.C., et al., Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med*, 2015. 372(10): p. 923-32.
37. Hickman, L.C., et al., Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists. *J Assist Reprod Genet*, 2018. 35(4): p. 571-581.
38. Lambertini, M., et al., Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. *J Clin Oncol*, 2018. 36(19): p. 1981-1990.
39. Kano, M., et al., AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. *Proc Natl Acad Sci U S A*, 2017. 114(9): p. E1688-E1697.

References

40. Woodruff, T.K., A win-win for women's reproductive health: A nonsteroidal contraceptive and fertoprotective neoadjuvant. *Proc Natl Acad Sci U S A*, 2017. 114(9): p. 2101-2102.
41. Gonfloni, S., et al., Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. *Nat Med*, 2009. 15(10): p. 1179-85.
42. Morgan, S., et al., Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. *Plos One*, 2013. 8(7).
43. Kerr, J.B., et al., Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. *Nat Med*, 2012. 18(8): p. 1170-2; author reply 1172-4.
44. Cherry, S.M., P.A. Hunt, and T.J. Hassold, Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation. *Mutat Res Genet Toxicol Environ Mutagen*, 2004. 564(2): p. 115-128.
45. Woodruff, T.K., Preserving fertility during cancer treatment. *Nat Med*, 2009. 15(10): p. 1124-5.
46. Wang-Rodriguez, J., et al., STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. *Laryngoscope*, 2006. 116(8): p. 1409-16.
47. Prockop, D.J., Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science*, 1997. 276(5309): p. 71-4.